What's new

Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised

May 12, 2025 - 08:33
 0
Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised
Read More

Tags:

Previous Article

Boots chairman ups stake amid $10bn Walgreens takeover deal

Next Article

Anchoring Peace: The Battle of Lake Champlain, the End of the War of 1812, and H...

Related Posts

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

May 7, 2025  0

Product Management Services (PMS) - Implementation of I...

May 6, 2025  0

Supporting innovation

Supporting innovation

May 8, 2025  0